Form 4: Akero Therapeutics Chief Development Officer Acquires Shares Through Employee Stock Purchase Plan

Akero Therapeutics' Chief Development Officer, Catriona Yale, acquired 890 shares of common stock through the company's Employee Stock Purchase Plan.

Summary

• Catriona Yale, the Chief Development Officer of Akero Therapeutics, Inc. (AKRO), acquired 890 shares of the company's common stock.
• The transaction occurred on June 30, 2025, and was reported on July 2, 2025.
• The shares were purchased at a price of $23.868 per share.
• This acquisition was made pursuant to the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan (ESPP).
• The purchase price of $23.868 represents 85% of the closing price of Akero Therapeutics' common stock on January 2, 2025.
• Following this transaction, Catriona Yale beneficially owns a total of 91,488 shares of Akero Therapeutics common stock.
• The acquisition was exempt under SEC Rule 16b-3(c) and Rule 16b-3(d).

Sentiment

Score: 7

Explanation: The acquisition of shares by a Chief Development Officer through an Employee Stock Purchase Plan is generally viewed positively as it indicates continued insider investment and alignment with shareholder interests, albeit a routine transaction.

Positives

• The acquisition of shares by a Chief Development Officer indicates continued insider investment and alignment with shareholder interests.
• Shares were acquired through an Employee Stock Purchase Plan (ESPP) at a discounted price of $23.868, which is beneficial for the employee.

Future Outlook

NA

Management Comments

• Ms. Yale is voluntarily reporting the acquisition of these shares on June 30, 2025 pursuant to the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(c) and Rule 16b-3(d).
• In accordance with the provisions of the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan, these shares were purchased at 85% of the closing price of the Issuer's common stock on January 2, 2025.

Industry Context

This transaction is a standard occurrence within publicly traded companies, particularly those offering Employee Stock Purchase Plans (ESPPs) as part of their compensation and retention strategies. Such plans are common across various industries, including biotechnology, to align employee interests with shareholder value.

Stakeholder Impact

• Shareholders: The transaction signals continued confidence from management, potentially reinforcing investor sentiment.
• Employees: The transaction highlights the benefits of the company's Employee Stock Purchase Plan, which can be a valuable component of employee compensation and retention.

Key Dates

Recommendation

Keywords

Akero Therapeutics, AKRO, Form 4, insider transaction, stock purchase, ESPP, employee stock purchase plan, beneficial ownership, Catriona Yale, Chief Development Officer